

Chiara Corti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2566514/publications.pdf>

Version: 2024-02-01

31
papers

852
citations

471509

17
h-index

526287

27
g-index

31
all docs

31
docs citations

31
times ranked

670
citing authors

#	ARTICLE	IF	CITATIONS
1	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky056.	2.9	71
2	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , 2020, 11, 719.	2.4	67
3	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	5.2	67
4	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	3.5	63
5	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 106, 102395.	7.7	60
6	SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021, 148, 316-327.	2.8	55
7	Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174.	2.8	49
8	Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.	7.7	46
9	Commentary: SARS-CoV-2 vaccines and cancer patients. <i>Annals of Oncology</i> , 2021, 32, 569-571.	1.2	43
10	Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022, 24, 809-817.	4.0	35
11	Antibody-Drug Conjugates for the Treatment of Breast Cancer. <i>Cancers</i> , 2021, 13, 2898.	3.7	34
12	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. <i>BMC Cancer</i> , 2018, 18, 935.	2.6	32
13	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.	4.1	31
14	Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 270-279.	4.3	29
15	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021, 99, 102253.	7.7	26
16	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1461.	4.1	25
17	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metaanalysis. <i>Cancer Treatment Reviews</i> , 2021, 97, 102205.	7.7	21
18	Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. <i>Pharmaceuticals</i> , 2021, 14, 884.	3.8	17

#	ARTICLE	IF	CITATIONS
19	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	4.4	15
20	Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	11
21	Columnar Cell Lesion and Apocrine Hyperplasia of the Breast: Is There a Common Origin? The Role of Prolactin-induced Protein. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 508-514.	1.2	11
22	Novel immune targets for the treatment of triple-negative breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 815-834.	3.4	11
23	Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?. <i>European Journal of Cancer</i> , 2022, 171, 25-42.	2.8	9
24	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 5829.	3.7	8
25	Adjuvant treatment of early male breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 594-602.	2.4	6
26	Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. <i>European Journal of Cancer</i> , 2022, 172, 332-339.	2.8	6
27	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. <i>European Journal of Cancer</i> , 2022, 166, 202-207.	2.8	4
28	Tubular Adenoma of the Breast. <i>Encyclopedia of Pathology</i> , 2018, , 1-6.	0.0	0
29	Lymphovascular invasion and extranodal tumor extension as risk indicators of breast cancer-related lymphedema.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12609-e12609.	1.6	0
30	Tubular Adenoma of the Breast. <i>Encyclopedia of Pathology</i> , 2020, , 379-384.	0.0	0
31	Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3063-3063.	1.6	0